Companies in #Epilepsy
Found 4 companies operating in this sector.
Actio Biosciences
PrivateGenetics-driven precision medicine company developing small molecule therapeutics for rare and common diseases. Pipeline includes KCNT1 inhibitor for epilepsy and TRPV4 inhibitor for Charcot-Marie-Tooth disease. Acquired by Jazz Pharmaceuticals for $820M.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into precision therapies for central nervous system (CNS) disorders, with a focus on epilepsy and broader neuroscience.
Public biopharma (Nasdaq: SUPN) developing and commercializing CNS therapeutics across epilepsy, migraine, Parkinson's disease, ADHD and postpartum depression; agreed to an all-stock merger with Indivior in 2026.
Services: Belgium-based global biopharmaceutical company specializing in central nervous system (CNS) and immunology diseases. Marketed products include Cimzia (immunology), Keppra, Vimpat, Briviact (epilepsy), and Rystiggo (myasthenia gravis). Active R&D pipeline in neurology, immunology, and rare diseases. Leadership: CEO (Cyril) - headquartered in Brussels, Belgium. EVP/Head of Neurology Charl van Zyl (departed for Lundbeck CEO role 2023). Keywords: Belgian biopharma, CNS, immunology, epilepsy, myasthenia gravis, Cimzia, Briviact